Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160637 | 0.85 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTL3MBTL1UHRF1 | |
| SCHEMBL7083266 | 0.82 | ALDH1A1 (0.40) | ALDH1A1KDM4EMAPTL3MBTL1UHRF1 | |
| SCHEMBL20812680 | 0.82 | CNR2 (0.59) | ALDH1A1KDM4EMAPTL3MBTL1UHRF1 | |
| SCHEMBL12677912 | 0.80 | ALDH1A1 (0.69) | ALDH1A1MAPTL3MBTL1UHRF1CCR1 | |
| SCHEMBL17297335 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTL3MBTL1UHRF1 | |
| SCHEMBL4947094 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL621293 | 0.79 | ALDH1A1 (0.68) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL803789 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL883789 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL5700562 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2024105363-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| WO-2024015251-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| CN-114456176-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114456175-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-09-06 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2009155565-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1765811-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | Bayer Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002383-A2 | 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | ALDH1A1 529/4885KDM4E 146/4885MAPT 1539/4885 |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | ALDH1A1 529/4885KDM4E 146/4885MAPT 1539/4885 |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | ALDH1A1 2375/4885KDM4E 2916/4885MAPT 608/4885 |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | ALDH1A1 2375/4885KDM4E 2916/4885MAPT 608/4885 |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | ALDH1A1 2375/4885KDM4E 2916/4885MAPT 608/4885 |
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | ALDH1A1 611/4885KDM4E 975/4885MAPT 4808/4885 |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | ALDH1A1 2375/4885KDM4E 2916/4885MAPT 608/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | ALDH1A1 529/4885KDM4E 146/4885MAPT 1539/4885 |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | ALDH1A1 529/4885KDM4E 146/4885MAPT 1539/4885 |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | EZH2, BMI1, EZH1 | ALDH1A1 738/4885KDM4E 80/4885MAPT 3346/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | ALDH1A1 2375/4885KDM4E 2916/4885MAPT 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.